Algernon wants to use psychedelics as a therapy for stroke victims. The post Algernon Pharmaceuticals Looks to Advance DMT Stroke Research appeared first...
The article Reunion Neuroscience Completes Data Analysis for Phase 1 Clinical Trial was originally published on Microdose. Reunion Neuroscience Completes...
It seems it is business as usual for Mind Medicine, aka MindMed, (NASDAQ: MNMD) as the firm gave updates on The post MindMed Expects Results For...
The article Secretive GH Research Provides Business Updates and Upcoming Milestones was originally published on Microdose. Secretive psychedelic drug...
Reunion will present findings to the FDA. The post Postpartum Depression Psychedelic Treatment Studied In Reunion’s Phase 1 Trial appeared first on Green...
The article Atai Announces Disappointing Results in PCN-101 Phase 2a Trial was originally published on Microdose. The industry has been waiting for these...
Atai plans to continue working with its compound despite the setback. The post Atai Life Sciences Ketamine Treatment for Depression Fails in Mid-Stage...
The article Algernon Forms Private Subsidiary to Advance DMT Stroke Program was originally published on Microdose. “By creating AGN Neuro with the sole...
With all the twists and turns coming from the U.S. federal government, decriminalization and legalization of psychedelics advancing all across the country,...
The article 2022 End-of-Year Review: MindMed was originally published on Microdose. Continuing our series of 2022 end-of-year reviews, we take a look...